How 10 breakthrough therapies by 2030 could transform patient care worldwide

Delivering 10 transformative therapies by 2030 is a long-term aspiration for Gilead Sciences and reflects a roadmap for addressing some of medicine’s most stubborn challenges. This strategy, which spans HIV prevention and treatment, cancer, and inflammatory diseases, shows how focused research combined with smart access planning could fundamentally change how we treat patients worldwide.

Gilead’s recent breakthrough with the first twice-yearly HIV prevention medication perfectly illustrates this approach. The injectable drug only needs to be administered twice a year, which may offer an important option for people who face challenges with daily pills.

In 2025, Gilead submitted regulatory filings for this prevention option in 18 countries, targeting regions that represent a significant share of global HIV cases.

Building on a proven track record

For decades, Gilead has been at the forefront of HIV treatment and prevention, and the company’s current research pushes even further. Several ongoing trials are testing ways to make HIV treatment and prevention simpler, more effective and more accessible to a broad range of people. These trials could help further transform HIV from something requiring daily attention to a condition managed with just a few doctor visits annually.

But Gilead’s vision extends well beyond HIV. In cancer, the company has a pipeline of CAR T-cell therapies that are designed to address important challenges with current treatments, such as relapse related to antigen loss. About 30% of patients who receive today’s CAR-T therapies eventually relapse because their cancer finds ways to hide from the engineered immune cells. Gilead’s newer investigational versions, KITE-363 and KITE-753, aim to target cancer cells in multiple ways to prevent this. Early studies are exploring whether these therapies might be given in outpatient clinics rather than requiring lengthy hospital stays, a change that could make these treatments more accessible if supported by future data and regulatory decisions.

Gilead is committed to addressing the profound unmet needs in metastatic triple-negative breast cancer (TNBC), a disease in which patients have long faced limited treatment options. Building on encouraging results from two recent Phase 3 first-line metastatic TNBC studies, Gilead’s research underscores a clear focus on advancing care for this aggressive and treatment-resistant cancer. As additional studies progress, there is meaningful potential for new therapeutic options that could improve outcomes and offer renewed hope for patients.

Getting medicines to those who need them most

Access planning is a core component of Gilead’s long-term strategy across its portfolio. Rather than focusing solely on approvals in high-income markets, the company works to integrate access considerations early, collaborating with governments, global health organizations, and local partners to address affordability, healthcare infrastructure, and delivery challenges across disease areas.

One illustration of this broader access strategy is Gilead’s approach to providing long-acting HIV prevention medication. In 2024, the company entered agreements with six generic manufacturers to support the future production of affordable versions of a twice-yearly HIV option for eligible low- and lower-middle-income countries. Early manufacturing support and technology sharing were intended to help reduce delays between regulatory decisions and potential availability, subject to review and readiness.

Partnerships with organizations like the U.S. State Department’s PEPFAR initiative and the Global Fund go beyond procuring drugs. These partnerships are ensuring collaboration on practical challenges like training healthcare workers to give injections and ensuring medicines reach remote clinics. After all, a breakthrough therapy can only reach its full potential if it reaches the people who could benefit most.

Tackling inflammation at its source

Gilead’s inflammation research takes a different approach: instead of managing only symptoms, these potential therapies aim to stop disease progression altogether. The pipeline now includes 13 assets, ranging from preclinical compounds to those in Phase 2 clinical trials, as well as one therapy approved for use in the U.S. for the liver condition known as primary biliary cholangitis or PBC.

By targeting the specific pathways that drive inflammation, these investigational drugs aim to reduce the scarring and tissue damage that contribute to the burden of these conditions.

The path ahead

What makes Gilead’s strategy compelling is how it approaches serious diseases from multiple angles. Across HIV, oncology, and inflammatory diseases, the company is advancing research aimed at reducing treatment burden, expanding therapeutic options, and addressing underlying disease drivers. Long-acting HIV prevention, next-generation CAR-T therapies, and inflammation research each reflect this broader, disease-focused approach.

As these programs advance through clinical trials, Gilead’s commitment to delivering 10 transformative therapies by 2030 represents a concentrated push to address multiple unmet medical needs simultaneously. By combining scientific innovation with thoughtful access planning, the company aims to ensure breakthroughs reach patients everywhere. The true measure of success won’t be patents filed, or drugs approved — it will be lives improved around the world.

Learn more about Gilead’s research at Gilead.com.